Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study

Ole Schmeltz Søgaard; Joanne Reekie; Isik Somuncu Johansen; Henrik Nielsen; Thomas Benfield; Lothar Wiese; Nina Breinholt Stærke; Kasper Iversen; Kamille Fogh; Jacob Bodilsen; Mette Iversen; Lene Surland Knudsen; Vibeke Klastrup; Fredrikke Dam Larsen; Sidsel Dahl Andersen; Astrid Korning Hvidt; Signe Rode Andreasen; Lone Wulff Madsen; Susan Olaf Lindvig; Anne Øvrehus; Sisse Rye Ostrowski; Christiane Abildgaard; Charlotte Matthews; Tomas O. Jensen; Dorthe Raben; Christian Erikstrup; Thea K. Fischer; Martin Tolstrup; Lars Østergaard; Jens Lundgren

doi:10.1016/j.cmi.2022.03.003

Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study

Ole Schmeltz Søgaard^*, Joanne Reekie, Isik Somuncu Johansen, Henrik Nielsen, Thomas Benfield, Lothar Wiese, Nina Breinholt Stærke, Kasper Iversen, Kamille Fogh, Jacob Bodilsen, Mette Iversen, Lene Surland Knudsen, Vibeke Klastrup, Fredrikke Dam Larsen, Sidsel Dahl Andersen, Astrid Korning Hvidt, Signe Rode Andreasen, Lone Wulff Madsen, Susan Olaf Lindvig, Anne ØvrehusSisse Rye Ostrowski, Christiane Abildgaard, Charlotte Matthews, Tomas O. Jensen, Dorthe Raben, Christian Erikstrup, Thea K. Fischer, Martin Tolstrup, Lars Østergaard, Jens Lundgren

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

30 Citations (Scopus)

29 Downloads (Pure)

Abstract

OBJECTIVES: To identify individual characteristics associated with serological COVID-19 vaccine responsiveness and durability of vaccine-induced antibodies.

METHODS: Adults without history of SARS-CoV-2 infection from the Danish population scheduled for SARS-CoV-2 vaccination were enrolled in this parallel group, phase IV study. SARS-CoV-2 Spike IgG and Spike-ACE2-receptor-blocking antibodies were measured at days 0, 21, 90 and 180. Vaccine responsiveness was categorized according to Spike IgG and Spike-ACE2-receptor-blocking levels at day 90 post-1st vaccination. Non-durable vaccine-response was defined as day 90 responders that no longer had significant responses by day 180.

RESULTS: Of 6544 participants completing two vaccine doses (median age 64, interquartile range:54-75), 3654 (55.8%) received BTN162b2, 2472 (37.8%) mRNA-1273, and 418 (6.4%) ChAdOx1 followed by a mRNA vaccine. Levels of both types of antibodies increased from baseline to day 90 and then decreased to day 180. The decrease was more pronounced for levels of Spike-ACE2-receptor-blocking antibodies than for Spike IgG. Proportions with vaccine hypo-responsiveness and lack of durable response were 5.0% and 12.1% for Spike IgG; 12.7% and 39.6% for Spike-ACE2-receptor-blocking antibody levels, respectively. Male sex, vaccine type and number of co-morbidities were associated with all four outcomes. Additionally, age >=75y was associated with hypo-responsiveness for Spike-ACE2-receptor-blocking antibodies (adjusted odds-ratio:1.59, 95% confidence interval:1.25-2.01) but not for Spike IgG.

CONCLUSIONS: Comorbidity, male sex and vaccine type were risk factors for hypo-responsiveness and non-durable response to COVID-19 vaccination. The functional activity of vaccine-induced antibodies declined with increasing age and had waned to pre-2nd vaccination levels for most individuals after 6 months.

Original language	English
Journal	Clinical Microbiology and Infection
Volume	28
Issue number	8
Pages (from-to)	1126-1133
Number of pages	8
ISSN	1198-743X
DOIs	https://doi.org/10.1016/j.cmi.2022.03.003
Publication status	Published - Aug 2022

Bibliographical note

Keywords

Antibody
COVID-19
Immunity
SARS-CoV-2
Vaccination
Antibodies, Viral/blood
Spike Glycoprotein, Coronavirus/immunology
Comorbidity
Humans
Immunoglobulin G
Middle Aged
Antibodies, Blocking
Male
COVID-19 Vaccines/immunology
mRNA Vaccines
Angiotensin-Converting Enzyme 2
Denmark/epidemiology
COVID-19/epidemiology
Female
Aged

Access to Document

10.1016/j.cmi.2022.03.003Licence: CC BY 4.0

Open Access articleFinal published version, 807 KBLicence: CC BY 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Søgaard, O. S., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Stærke, N. B., Iversen, K., Fogh, K., Bodilsen, J., Iversen, M., Knudsen, L. S., Klastrup, V., Larsen, F. D., Andersen, S. D., Hvidt, A. K., Andreasen, S. R., Madsen, L. W., Lindvig, S. O., ... Lundgren, J. (2022). Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study. Clinical Microbiology and Infection, 28(8), 1126-1133. Advance online publication. https://doi.org/10.1016/j.cmi.2022.03.003

@article{ef559fbed833474780878ae03a99bcd8,

title = "Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study",

abstract = "OBJECTIVES: To identify individual characteristics associated with serological COVID-19 vaccine responsiveness and durability of vaccine-induced antibodies.METHODS: Adults without history of SARS-CoV-2 infection from the Danish population scheduled for SARS-CoV-2 vaccination were enrolled in this parallel group, phase IV study. SARS-CoV-2 Spike IgG and Spike-ACE2-receptor-blocking antibodies were measured at days 0, 21, 90 and 180. Vaccine responsiveness was categorized according to Spike IgG and Spike-ACE2-receptor-blocking levels at day 90 post-1st vaccination. Non-durable vaccine-response was defined as day 90 responders that no longer had significant responses by day 180.RESULTS: Of 6544 participants completing two vaccine doses (median age 64, interquartile range:54-75), 3654 (55.8%) received BTN162b2, 2472 (37.8%) mRNA-1273, and 418 (6.4%) ChAdOx1 followed by a mRNA vaccine. Levels of both types of antibodies increased from baseline to day 90 and then decreased to day 180. The decrease was more pronounced for levels of Spike-ACE2-receptor-blocking antibodies than for Spike IgG. Proportions with vaccine hypo-responsiveness and lack of durable response were 5.0% and 12.1% for Spike IgG; 12.7% and 39.6% for Spike-ACE2-receptor-blocking antibody levels, respectively. Male sex, vaccine type and number of co-morbidities were associated with all four outcomes. Additionally, age >=75y was associated with hypo-responsiveness for Spike-ACE2-receptor-blocking antibodies (adjusted odds-ratio:1.59, 95% confidence interval:1.25-2.01) but not for Spike IgG.CONCLUSIONS: Comorbidity, male sex and vaccine type were risk factors for hypo-responsiveness and non-durable response to COVID-19 vaccination. The functional activity of vaccine-induced antibodies declined with increasing age and had waned to pre-2nd vaccination levels for most individuals after 6 months.",

keywords = "Antibody, COVID-19, Immunity, SARS-CoV-2, Vaccination, Antibodies, Viral/blood, Spike Glycoprotein, Coronavirus/immunology, Comorbidity, Humans, Immunoglobulin G, Middle Aged, Antibodies, Blocking, Male, COVID-19 Vaccines/immunology, mRNA Vaccines, Angiotensin-Converting Enzyme 2, Denmark/epidemiology, COVID-19/epidemiology, Female, Aged",

author = "S{\o}gaard, {Ole Schmeltz} and Joanne Reekie and Johansen, {Isik Somuncu} and Henrik Nielsen and Thomas Benfield and Lothar Wiese and St{\ae}rke, {Nina Breinholt} and Kasper Iversen and Kamille Fogh and Jacob Bodilsen and Mette Iversen and Knudsen, {Lene Surland} and Vibeke Klastrup and Larsen, {Fredrikke Dam} and Andersen, {Sidsel Dahl} and Hvidt, {Astrid Korning} and Andreasen, {Signe Rode} and Madsen, {Lone Wulff} and Lindvig, {Susan Olaf} and Anne {\O}vrehus and Ostrowski, {Sisse Rye} and Christiane Abildgaard and Charlotte Matthews and Jensen, {Tomas O.} and Dorthe Raben and Christian Erikstrup and Fischer, {Thea K.} and Martin Tolstrup and Lars {\O}stergaard and Jens Lundgren",

year = "2022",

month = aug,

doi = "10.1016/j.cmi.2022.03.003",

language = "English",

volume = "28",

pages = "1126--1133",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Pergamon Press",

number = "8",

}

Søgaard, OS, Reekie, J, Johansen, IS, Nielsen, H, Benfield, T, Wiese, L, Stærke, NB, Iversen, K, Fogh, K, Bodilsen, J, Iversen, M, Knudsen, LS, Klastrup, V, Larsen, FD, Andersen, SD, Hvidt, AK, Andreasen, SR, Madsen, LW, Lindvig, SO, Øvrehus, A, Ostrowski, SR, Abildgaard, C, Matthews, C, Jensen, TO, Raben, D, Erikstrup, C, Fischer, TK, Tolstrup, M, Østergaard, L & Lundgren, J 2022, 'Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study', Clinical Microbiology and Infection, vol. 28, no. 8, pp. 1126-1133. https://doi.org/10.1016/j.cmi.2022.03.003

Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study. / Søgaard, Ole Schmeltz; Reekie, Joanne; Johansen, Isik Somuncu et al.
In: Clinical Microbiology and Infection, Vol. 28, No. 8, 08.2022, p. 1126-1133.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity

T2 - The Danish Nationwide ENFORCE Study

AU - Søgaard, Ole Schmeltz

AU - Reekie, Joanne

AU - Johansen, Isik Somuncu

AU - Nielsen, Henrik

AU - Benfield, Thomas

AU - Wiese, Lothar

AU - Stærke, Nina Breinholt

AU - Iversen, Kasper

AU - Fogh, Kamille

AU - Bodilsen, Jacob

AU - Iversen, Mette

AU - Knudsen, Lene Surland

AU - Klastrup, Vibeke

AU - Larsen, Fredrikke Dam

AU - Andersen, Sidsel Dahl

AU - Hvidt, Astrid Korning

AU - Andreasen, Signe Rode

AU - Madsen, Lone Wulff

AU - Lindvig, Susan Olaf

AU - Øvrehus, Anne

AU - Ostrowski, Sisse Rye

AU - Abildgaard, Christiane

AU - Matthews, Charlotte

AU - Jensen, Tomas O.

AU - Raben, Dorthe

AU - Erikstrup, Christian

AU - Fischer, Thea K.

AU - Tolstrup, Martin

AU - Østergaard, Lars

AU - Lundgren, Jens

PY - 2022/8

Y1 - 2022/8

N2 - OBJECTIVES: To identify individual characteristics associated with serological COVID-19 vaccine responsiveness and durability of vaccine-induced antibodies.METHODS: Adults without history of SARS-CoV-2 infection from the Danish population scheduled for SARS-CoV-2 vaccination were enrolled in this parallel group, phase IV study. SARS-CoV-2 Spike IgG and Spike-ACE2-receptor-blocking antibodies were measured at days 0, 21, 90 and 180. Vaccine responsiveness was categorized according to Spike IgG and Spike-ACE2-receptor-blocking levels at day 90 post-1st vaccination. Non-durable vaccine-response was defined as day 90 responders that no longer had significant responses by day 180.RESULTS: Of 6544 participants completing two vaccine doses (median age 64, interquartile range:54-75), 3654 (55.8%) received BTN162b2, 2472 (37.8%) mRNA-1273, and 418 (6.4%) ChAdOx1 followed by a mRNA vaccine. Levels of both types of antibodies increased from baseline to day 90 and then decreased to day 180. The decrease was more pronounced for levels of Spike-ACE2-receptor-blocking antibodies than for Spike IgG. Proportions with vaccine hypo-responsiveness and lack of durable response were 5.0% and 12.1% for Spike IgG; 12.7% and 39.6% for Spike-ACE2-receptor-blocking antibody levels, respectively. Male sex, vaccine type and number of co-morbidities were associated with all four outcomes. Additionally, age >=75y was associated with hypo-responsiveness for Spike-ACE2-receptor-blocking antibodies (adjusted odds-ratio:1.59, 95% confidence interval:1.25-2.01) but not for Spike IgG.CONCLUSIONS: Comorbidity, male sex and vaccine type were risk factors for hypo-responsiveness and non-durable response to COVID-19 vaccination. The functional activity of vaccine-induced antibodies declined with increasing age and had waned to pre-2nd vaccination levels for most individuals after 6 months.

AB - OBJECTIVES: To identify individual characteristics associated with serological COVID-19 vaccine responsiveness and durability of vaccine-induced antibodies.METHODS: Adults without history of SARS-CoV-2 infection from the Danish population scheduled for SARS-CoV-2 vaccination were enrolled in this parallel group, phase IV study. SARS-CoV-2 Spike IgG and Spike-ACE2-receptor-blocking antibodies were measured at days 0, 21, 90 and 180. Vaccine responsiveness was categorized according to Spike IgG and Spike-ACE2-receptor-blocking levels at day 90 post-1st vaccination. Non-durable vaccine-response was defined as day 90 responders that no longer had significant responses by day 180.RESULTS: Of 6544 participants completing two vaccine doses (median age 64, interquartile range:54-75), 3654 (55.8%) received BTN162b2, 2472 (37.8%) mRNA-1273, and 418 (6.4%) ChAdOx1 followed by a mRNA vaccine. Levels of both types of antibodies increased from baseline to day 90 and then decreased to day 180. The decrease was more pronounced for levels of Spike-ACE2-receptor-blocking antibodies than for Spike IgG. Proportions with vaccine hypo-responsiveness and lack of durable response were 5.0% and 12.1% for Spike IgG; 12.7% and 39.6% for Spike-ACE2-receptor-blocking antibody levels, respectively. Male sex, vaccine type and number of co-morbidities were associated with all four outcomes. Additionally, age >=75y was associated with hypo-responsiveness for Spike-ACE2-receptor-blocking antibodies (adjusted odds-ratio:1.59, 95% confidence interval:1.25-2.01) but not for Spike IgG.CONCLUSIONS: Comorbidity, male sex and vaccine type were risk factors for hypo-responsiveness and non-durable response to COVID-19 vaccination. The functional activity of vaccine-induced antibodies declined with increasing age and had waned to pre-2nd vaccination levels for most individuals after 6 months.

KW - Antibody

KW - COVID-19

KW - Immunity

KW - SARS-CoV-2

KW - Vaccination

KW - Antibodies, Viral/blood

KW - Spike Glycoprotein, Coronavirus/immunology

KW - Comorbidity

KW - Humans

KW - Immunoglobulin G

KW - Middle Aged

KW - Antibodies, Blocking

KW - Male

KW - COVID-19 Vaccines/immunology

KW - mRNA Vaccines

KW - Angiotensin-Converting Enzyme 2

KW - Denmark/epidemiology

KW - COVID-19/epidemiology

KW - Female

KW - Aged

UR - http://www.scopus.com/inward/record.url?scp=85127561603&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2022.03.003

DO - 10.1016/j.cmi.2022.03.003

M3 - Journal article

C2 - 35283313

SN - 1198-743X

VL - 28

SP - 1126

EP - 1133

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 8

ER -

Characteristics Associated with Serological Covid-19 Vaccine Response and Durability in an Older Population with Significant Comorbidity: The Danish Nationwide ENFORCE Study

Abstract

Bibliographical note

Keywords

Access to Document

AUB Link

Other files and links

Fingerprint

Cite this